Major trial tests new drug combo to stop aggressive breast Cancer's return
NCT ID NCT07441460
Summary
This large study is testing whether a new combination of two drugs (KN026 and HB1801) plus standard chemotherapy works better than the current standard drug combination to prevent cancer from coming back after surgery. It involves 1,800 people with a specific, aggressive type of breast cancer (HER2-positive) that has spread to their lymph nodes. The goal is to see which treatment is more effective at keeping patients cancer-free after their initial tumor is removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 201318, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.